ATWLPPR Peptide TFA |
| Catalog No.GC34219 |
ATWLPPR 펩티드 TFA는 헵타펩티드로 선택적 뉴로필린-1 억제제로 작용하여 혈관신생 연구에 사용되는 VEGF165가 NRP-1에 결합하는 것을 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis[1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes[2].
ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1 by 82% at 100 μM[1].
ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes[2].ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) in the retina[2].
[1]. Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402. [2]. Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *